{"filing":{"accession_number":"0001140361-26-034320","cik":"0001472091","ticker":"PDSB","company_name":"PDS Biotechnology Corp","form":"8-K","filing_date":"2026-08-25","report_date":"2026-08-21","primary_document":"ef20081077_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126034320/ef20081077_8k.htm"},"events":[{"id":29466,"run_id":26984,"accession_number":"0001140361-26-034320","anchor_item_number":"2.05","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"The Board approved a reduction in force affecting approximately 36% of the workforce, with an estimated one-time charge of $842,000 for employee separation benefits.","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-08-25","form":"8-K","submitted_at":null,"items":[{"id":31760,"accession_number":"0001140361-26-034320","item_number":"2.05","item_title":null,"event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The disclosure describes a Board-approved reduction in force affecting approximately 36% of the workforce, with an estimated one-time charge of $842,000 for employee separation benefits. This is a classic workforce reduction event under Item 2.05, combining both the operational decision and the associated restructuring charge. The magnitude (over one-third of workforce) and quantified financial impact make this material to investors assessing the company's cost structure and strategic repositioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:11:54.888214+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":29467,"run_id":26984,"accession_number":"0001140361-26-034320","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Stephan Toutain was terminated without cause from his position as Chief Operating Officer on August 21, 2026, triggering severance benefit obligations.","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-08-25","form":"8-K","submitted_at":null,"items":[{"id":31761,"accession_number":"0001140361-26-034320","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the termination without cause of Stephan Toutain from his position as Chief Operating Officer on August 21, 2026. While severance benefits are mentioned, the principal disclosed action is the departure of a named executive officer from a senior leadership role, making this an exec_departure event. The material nature is evident from the executive's rank and the severance obligations triggered.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:11:54.888214+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31760,"accession_number":"0001140361-26-034320","item_number":"2.05","item_title":null,"event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The disclosure describes a Board-approved reduction in force affecting approximately 36% of the workforce, with an estimated one-time charge of $842,000 for employee separation benefits. This is a classic workforce reduction event under Item 2.05, combining both the operational decision and the associated restructuring charge. The magnitude (over one-third of workforce) and quantified financial impact make this material to investors assessing the company's cost structure and strategic repositioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:11:54.888214+00:00","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-08-25"},{"id":31761,"accession_number":"0001140361-26-034320","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the termination without cause of Stephan Toutain from his position as Chief Operating Officer on August 21, 2026. While severance benefits are mentioned, the principal disclosed action is the departure of a named executive officer from a senior leadership role, making this an exec_departure event. The material nature is evident from the executive's rank and the severance obligations triggered.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:11:54.888214+00:00","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-08-25"}]}